1.Reduced growth of Lucilia cuprina larvae fed serum from sheep treated with anthelmintics.
East IJ;Kerlin RL;Eisemann CH Aust Vet J. 1992 Nov;69(11):286-7.
The effect of three commonly used anthelmintics, levamisole hydrochloride, ivermectin and closantel, on the development of the sheep blowfly, Lucilia cuprina, was determined. Sheep were treated with each anthelmintic using the manufacturers' recommended dose for helminth control. Both ivermectin and closantel significantly (p < 0.05) reduced the growth rate of larvae of L cuprina cultured in vitro on serum from these sheep. Levamisole hydrochloride had no effect. Ivermectin was effective for less than 6 days after treatment, whereas closantel significantly reduced larval growth 21 days after treatment. Dose-response experiments showed that lower concentrations of both ivermectin and closantel were not as effective in reducing larval growth.
2.Chemotherapeutic studies on Litomosoides carinii infection of Mastomys natalensis. 2. The activity of drugs against microfilariae.
Lämmler G;Herzog H;Schütze HR Bull World Health Organ. 1971;44(6):757-63.
Comparative investigations of the chemotherapeutic activity of various filaricidal compounds and other anthelmintics were made with Litomosoides carinii infections in Mastomys natalensis, special consideration being given to the microfilaricidal activity of the compounds. Diethylcarbamazine, cyclohexanecarboxylic acid-N-methylpiperazide citrate (HOE 28637a), tetrahydropyranecarboxylic acid-N-methylpiperazide citrate (HOE 29691a), (+/-)-tetramisole, (-)-tetramisole (levamisole), and metrifonate proved highly effective against microfilariae whereas gentian violet, methylene violet, and the anthelmintics metyridine, disophenol, pyrantel tartrate, methylpyrantel tartrate and parbendazole showed no, or only inadequate, activity. The usefulness of L. carinii infections in M. natalensis is discussed and is recommended as a model for chemotherapeutic screening tests and for the quantitative evaluation of microfilaricidal activity.
3.Colorectal cancer. Recent developments and continuing controversies.
Lee MW Postgrad Med. 1992 Jan;91(1):153-5, 159-60.
In the last 2 years, much progress has been made in colorectal cancer research. Many of the findings, especially those involving adjuvant therapy, have important clinical applications. For example, fluorouracil (5-FU) (Adrucil) combined with levamisole hydrochloride (Ergamisol) is now recommended as adjuvant therapy for patients with Dukes' stage C (III) disease. Some aspects of colorectal cancer remain controversial, particularly screening recommendations and monitoring of carcinoembryonic antigen levels.
